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Abstract
Background: After total mesorectal excision (TME) for rectal cancer around 10% of patients
develops local recurrences within the pelvis. One reason for recurrence might be spillage of cancer
cells during surgery. This pilot study was conducted to investigate the incidence of remnant cancer
cells in pelvic lavage after resection of rectal cancer. DNA from cells obtained by lavage, were
analysed by denaturing capillary electrophoresis with respect to mutations in hotspots of the k-ras
gene, which are frequently mutated in colorectal cancer.
Results: Of the 237 rectal cancer patients analyzed, 19 had positive lavage fluid. There was a
significant survival difference (p = 0.006) between patients with k-ras positive and negative lavage
fluid.
Conclusion: Patients with k-ras mutated cells in the lavage immediately after surgery have a
reduced life expectation. Detection of exfoliated cells in the abdominal cavity may be a useful
diagnostic tool to improve the staging and eventually characterize patients who may benefit from
aggressive multimodal treatment of rectal cancer.
Background
Cancer of the rectum is frequent in both genders and the
incidence in Norway is still increasing, with a total of
1137 new cases in a population of 4.6 million citizens in
2004 [1]. Survival in cancer of rectum has continuously
improved in the past ten year period [1,2]. The main rea-
sons for this is the introduction of total mesorectal exci-
sion (TME) [3] and better staging with adjuvant treatment
for patient in high risk groups [4]. In spite of such
improvement, local recurrence after potentially curative
surgery is a major problem. There are several possible
causes for local recurrences including: incomplete resec-
tion of the primary carcinoma [4,5], insufficient removal
of involved regional lymph nodes [6], development of a
secondary tumour near the suture site and exfoliated can-
cer cells released at the time of surgery [7]. Dissemination
of tumour cells in the presacral space, as well as in tumour
lymphatic drainage and in peripheral blood vessels after
resection of the tumour, might play a role in the metasta-
sis process, thus affecting the clinical course. Previous
reports have indicated that tumours can release DNA into
the circulation [8-10]. Hence, recovery of mutated cell by
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sized to be of prognostic value. One of the most promi-
nent mutated genes in colorectal cancer is Kirsten ras 2 (k-
ras), a member of the RAS family. Mutations in the k-ras
gene is described as an early event in the process of color-
ectal carcinogenesis [11]. K-ras mutations are mainly
found in exon 1, codon 12, 13 and exon 2, codon 61.
Mutations in codon 12 account for 80–90% of k-ras gene
alterations with several hotspots [12]. Oncogenic muta-
tions of k-ras are involved in 20–50% of colorectal cancers
[13,14]. The k-ras mutation frequency in rectal cancer has
been reported to be 15–33% which is lower than in colon
cancer [15,16]. We used k-ras exon 1 as the only tumour
cell-associated marker to determine the presence of dis-
seminated tumour cells in peritoneal lavage samples from
patients undergoing surgery for rectal cancer. The aim of
this pilot study was to evaluate the method denaturant
capillary electrophoresis (DCE), to detect tumour cells in
peritoneal lavage fluid of patients undergoing resection
for rectal cancer.
Methods
Study population
The University Hospital Rikshospitalet-Radiumhospitalet
is a tertiary referral center for locally advanced primary
and recurrent rectal cancer. The treatment regime is multi-
modal and includes preoperative radiotherapy or chemo-
radiation.
Our patients undergo surgery a median 56 days after end
of long course radiation therapy.
Peritoneal lavage from 237 patients and tumour samples
from 186 patients (59% men, 41% women) with either
locally advanced or local recurrent rectal cancer was col-
lected during surgery at the Norwegian Radium Hospital
between 2000 and 2006. Patient's age ranged from 29 to
87 years with a median age of 66. All samples were col-
lected after written informed consent. Possible risk factors
for dissemination of cancer cells intraoperatively were reg-
istered: resection through the periphery of the cancer as in
R1 and R2 resections, tumour perforation or the presence
of lymph node metastases in the mesorectum. Penetration
of cancer through the serosa and the presence of macro-
scopic peritoneal carsinomatosis may of course give rise to
free cancer cells and were thoroughly registrated. Two
cases with registrated peritoneal carsinomatosis were
tested as "positive controls". Tumours were pathologically
staged according to the TNM classification [17] except for
the local recurrences that do not fit into this except for
pTo. This is due to the observation that a recurrence usu-
ally starts outside the rectal wall and most often there are
no lymph nodes to resect [18]. The local surgical achieve-
ments were staged as follows: R0 microscopically free cir-
cumferential and distal margins, R1 microscopically
involved margins, and R2 locally macroscopic residual
cancer or no resection. N0; No regional lymph node
metastasis. N1; Metastasis in 1 to 3 regional lymph nodes.
N2; Metastasis in 4 or more regional lymph nodes. NX;
unknown status of lymph nodes.
Sample treatment
After resection of the tumour the pelvis was washed with
sterile water 200–600 ml (discarded) subsequently fol-
lowed by 200–600 ml saline water. Thereafter two speci-
mens of 50 ml were aspirated to 50 ml centrifuge tubes.
The second sample of 50 ml most often contained more
white blood cells than the first sample because haemosta-
sis was not complete. Cells were harvested by centrifuga-
tion at 1200 g for 10 minutes followed by removal of the
supernatant. The cell pellets were frozen at -20°C until
DNA extractions were performed. QIAamp DNA Kit (Qia-
gen, Valencia, California, USA) was used for the DNA
extraction, following the manufacturers instructions.
Polymerase chain reaction
The target sequences were amplified through a nested PCR
protocol to circumvent amplification of a pseudogene.
Primers were designed with use of Primer 3 [18,19]. The
first PCR reaction consisted of approximately 50 ng
genomic DNA, 0.05 U/μl Taq, polymerase, 0.005 U/μl
PFU polymerase, 1× Buffer (ABgene), 2.5 mM MgCl2, and
0.4 mM dNTP mix (ABgene) and 0.15 μM of each primer
(5'CTTAAGCGTCGATGGAGGAG3',
5'AGAATGGTCCTGCACCAGTAA3'). The second PCR
used a 1:1000 dilution of the first PCR products as tem-
plate while the polymerase, buffer, MgCl2 and dNTP con-
centrations stayed the same. Primers, one labelled primer
with GC-clamp (5'- 6Fam-CGCCCGCCGCGCCCCGCGC
CCGTCCCGCCGCCCCCGCCCGCCTCTATTGTTGGATC
ATATTC3') at a final concentration of 0.11 μM and one
reveres primer (5'CATTATTTTTATTATAAGG3') in a final
concentration 0.3 μM were added to the mix. The total
volumes of both PCR reactions were adjusted to 10 μl
with sterile water. Temperature cycling was performed in
a Mastercycler® (Eppendorf, Bergman AS, Lillestrøm, Nor-
way) using the following cycling conditions: denaturation
5 min at 96°C, followed by 35 cycles of 95°C in 30 s,
annealing 56°C in 30s (first PCR) and 48°C in 30s (sec-
ond PCR) and 72°C in 60s.
We also analysed k-ras exon 2, and braf exon 11 and exon
15, but were unable to find any mutations with these
markers in the lavage samples.
Mutation detection
Amplified 6-fam labelled PCR products were analysed by
denaturant capillary electrophoresis in a MegaBACE 1000
DNA Analysis System (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). The base substitutions were separatedPage 2 of 8
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with mean separating temperatures of 48.5°C and ampli-
tudes of 3°C cycled 20 times. K-ras mutations in exon 1
were identified by co-analysis with a mutated internal
standard in a similar manner as previously described by
Bjørheim et al. [20]. Additionally, samples with a high
mutant fraction were sequenced according to standard
DNA sequencing protocol (GE Healthcare Bio-Sciences
AB).
Follow-up
The patients were followed for five years with X-ray of the
chest and CT of the pelvis and abdomen every three to six
months for five years or to the end of the study period.
Data concerning death was crosschecked with the
national health register.
Statistics
Patient's data were prospectively registered in a database.
All data was analyzed using the Statistical Package SPSS
12.5 for Windows. The chi-squared tests were used for sta-
tistical analysis and differences were considered signifi-
cant at P < 0.05. For survival analysis, Kaplain-Meiers
curves were constructed, and using the log-rank test
assessed differences in survival between groups.
Results
The clinical pathological characteristics of the 237 rectal
cancer patients are summarized in Table 1. Of the eleven
possible risk factors tested with regard to patients with
positive and negative k-ras markers in the lavage fluid,
only N- and R-stage were significantly different between
the two groups (p = 0.03 and p = 0.002, respectively). This
was mainly due to a higher percentage of N0 and R0 stages
in the k-ras negative group. We analyzed 186 of the
removed tumours for k-ras mutations and 56 of these were
k-ras positive. 19 out of 237 patients had a positive k-ras
marker in the lavage fluid (Table 2). Of the 19 cases with
k-ras positive lavage there were 12 R0, 3 R1 and 4 R2. We
have estimated survival rate for the patients with positive
and negative marker for lavage fluid by a Kaplan-Meier
plot (Figure 1) and a log rank test. Mean observation time
was 25 (1–66) months for all patients. Patients positive
for the marker in the lavage fluid had a mean survival of
22 months with a Std. Error 3.7 (C.I 14.6–29.1) months
compared to 47 months with a Std. Error 2.4 (C.I 43.2–
50.8) for patients with a negative marker (p = 0.006). As
R1 and R2 resections are more likely to have positive lav-
age fluid a new log rank test was done with only R0
patients. The result showed that there was still a signifi-
cant difference between the two groups (p = 0.02).
There was no significant difference (p = 0.3) between k-ras
positive and negative tumours with respect to survival
(Figure 1b). Likewise when mutational status of k-ras for
the tumour was compared for R0, the non-significant role
was maintained (p = 0.09).
In two of the cases of R0 resections with k-ras positive lav-
age the preoperative biopsy was classified as k-ras negative
being either a result of non-representative biopsy or a
multi-clonal locally advanced tumour.
A. K-ras in lavage samples immediately after surgery related to su vivalFig e 1
A. K-ras in lavage samples immediately after surgery related 
to survival. B. K-ras in tumours samples from rectal cancers 
patients related to survival.
A
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This study accessed the incidence of free colorectal cancer
cells or remnants of such cells in the pelvic cavity imme-
diately after surgery, and correlates their presence with
several clinicopathological parameters and survival. A sig-
nificant number of local recurrences following rectal can-
cer surgery cannot be explained by incomplete resection,
lymphatic or vascular invasion [21]. This suggests that via-
ble tumour cells with proliferate and perhaps metastatic
potential have been shed from the primary tumour site
either before removal of the tumour or during the surgical
procedure. In our study we found that 19 rectal cancer
patients had disseminated tumour cells in the 237 lavage
fluids from the rectal patients. And we found that these
patients with invisible tumour material in abdomen
immediately after surgery tend to have a worse prognosis
than patients without free tumour cells that could not be
explained by differences in other risk factors. Only N- and
R-stage were statistically significantly different between
the k-ras positive and negative groups. In both cases this
should be to the advantage of the k-ras negative group
containing relatively more N0 and R0 stages.
Table 1: Clinical and pathologic parameters in patients with positive and negative k-ras mutations.
k-ras marker 
Positive
k-ras marker 
Negative
P
Gender male/female 12/7 127/91 n.s
Age mean ± st.dv 65,8 ± 9.3 64.8 ± 11.8 n.s
Operation technique
APR 7 88 n.s
LAR 6 79
Hartmann's procedure 3 41
EkspI.lap 2 4
Tumour reduction 1 6
Primary rectal cancer 13 176 n.s
Locally recurrent rectal cancer 6 42
pT0-T1 0 19 n.s
pT2 2 21
pT3 9 105
pTx 8 47
N0 6 125 p = 0.03
N1/N2 6 64
NX 7 24
M0 15 180 n.s
M1 4 38
R0 12 155 p = 0.002
R1 3 56
R2 4 7
Distant metastasis during follow-up 4 70 n.s
Local recurrence during follow-up 7 31 n.s
Tumour perforation 5 37 n.s
APR: Abdominoperineal resection
LAR: Low anterior resection
EkspI. Lap: Explorative laparotomy
Local recurrence in this study means locally recurrent in the pelvis.
Distant metastasis in this study is distant metastasis or peritoneal carsinomatose.Page 4 of 8
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are well known indicators of recurrence and survival.
However, our results showed that 12 of the 19 positive k-
ras cases were R0 resections, which was an unpredicted
result. Resection into the circumference of macroscopic
(R2 resection) or microscopic tumour (R1 resection) or
into the depth of the tumour can of course contribute to
disseminated cells in the peritoneal cavity as well as is in
cases with tumour penetration of serosa or in overt perito-
neal carcinomatosis. As there were relatively more R0
stage resections in the k-ras negative group this is unlikely
to explain our finding. Lymph node metastases might
contribute by the shedding of cancer cells from a surgi-
cally severed lymphatic vessel. Several groups have
observed a relationship between the number of lymph
nodes identified at pathological examination and survival
Table 2: Clinical and pathologic information for the 19 patients with a positive k-ras marker in the lavage fluid.
Age Gender Operation 
tecnique
Sample 
status *
Recurrent♣ Tumour 
perforation
Metastatic T R N Serosa 
infiltration
Peretenoal 
carcino-
matose
Time 
(months 
observed)
Status
69 M LAR primary yes yes no T3 R0 N0 no no 26 Dead
64 M APR primary no no no T3 R0 N2 no no 39 Dead
76 M APR primary no yes no T3 R0 N1 no no 11 Dead
71 K Hartmann local 
recurrent
no no no unknown R0 Nx yes no 19 Dead
61 F APR local 
recurrent
no no no unknown R0 Nx no no 16 Dead
60 F LAR primary no no no T3 R0 N1 no no 15 Alive
77 M LAR primary no no no T3 R0 N0 no no 12 Alive
64 F LAR primary no no no T3 R0 N2 no no 11 Alive
49 F APR primary no no no T3 R0 N2 no no 4 Alive
60 M APR primary no no yes T2 R0 N1 no no 8 Alive
68 M LAR primary no no no T2 R0 N0 no no 3 Alive
71 M APR primary no no no T3 R0 N0 no no 3 Alive
61 M TumorRes local 
recurrent
yes yes yes unknown R1 Nx no no 22 Dead
82 M APR local 
recurrent
no no no T4 R1 Nx no no 18 Alive
59 F LAR primary no no no T3 R1 N0 possible unsertain 3 Alive
46 K Hartmann primary yes yes yes T4 R2 N0 no yes 21 Alive
66 M EksplLap primary yes unknown yes T4 R2 Nx unknown yes 1 Dead
69 M EksplLap local 
recurrent
yes no no unknown R2 unknown no no 18 Dead
78 M Hartmann local 
recurrent
yes yes no T4 R2 Nx no no 2 Dead
APR: Abdominoperineal resection, LAR: Low anterior resection, EkspI. Lap: Explorative laparotomy
* Sample status describes when the patient's tumour is classified either as a primary or a local recurrence.
♣ Recurrent describes whether or not the patients have developed a local recurrence after the surgery (when samples were retrieved).Page 5 of 8
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age of N0 stage in the k-ras negative group could not
explain the difference either. In our study there was no sig-
nificant difference in estimated survival, but a possible
trend observed between patients with k-ras positive and k-
ras negative tumor markers in the solid tumor samples.
This may rest upon the fact that the plots are more or less
similar until 30 months postoperatively and diverge after
this observation time. Thus within the observed period a
k-ras mutation in the tumor itself does not explain the
prognostic differences of the patients. In this study we
have found that patients with tumour cells in abdomen
after operation tend to have a worse prognosis than
patients without free tumour cells. Our results in this
study are similar to those of some studies with regard to
survival [24-27], but in conflict with other results [28,29].
These differences could be related to patient selection and
the methods used for detection as well as the follow-up
methods.
It has become apparent in recent years that not only do
the pathologic characteristics of rectal cancer influence the
long-term outcome in terms of local recurrence and sur-
vival, but also that the surgeon is an important variable.
This previously has been demonstrated by the reports
from the Norwegian Rectal Cancer Group [30,31]. Better
treatment, specialist care, recruitment into clinical trials or
treatment protocols and any combination of these factors
almost certainly influence regional variations in cancer
outcome. The Norwegian Radium Hospital is a compre-
hensive cancer centre with high-volume surgery and the
rectal cancers patient population is mostly TNM stage II
and III. In this pilot study only rectal cancer patients have
been included.
The detection of disseminated tumour cells depends on a
number of steps including collection and treatment of
samples, cell separation protocols and chosen markers.
Technical advancements in detecting free DNA have been
made over the years. All methods used depend on the rec-
ognition of antigens or gene markers assumed to be exclu-
sively expressed by tumour cells and not by normal tissue
in the examined sample. A cytology based method can
only detect nanogram quantities of DNA. Immunohisto-
chemistry leads to an increased sensitivity, but without
improved specificity. High number of false positives due
to non specific labelling was still observed and low sensi-
tivity and specificity contribute to the conflicting results
previously reported in detection of disseminated tumour
cells [25,28,29]. With the introduction of PCR, smaller
quantities of DNA could be detected. The robustness of
such analysis has been improved by fluorescence-based
allelotyping techniques involving capillary electrophore-
sis. These molecular detection methods can be divided in
two groups: Detection of RNA with marker-gene expres-
sion (m-RNA) and detection of RNA specific to the tissue.
This is a sensitive method with a possible detection of one
single mutated cell in up to 108 wild-type cells in an opti-
mal condition. However RNA is unstable in the extracel-
lular environment and its detection in tissue or fluids is
thus dependent on the presence of viable tumour cells.
Routinely performed clinical sampling methods such as
lavage may not be capable to preserve the RNA capacity of
the cells. The other method is detection of tumour specific
chromosomal abnormalities or mutations. In solid
tumours these variations are heterogenous and complex
with a need for detecting mutations in a small fraction.
We have previously demonstrated that the DCE method
used in this study fulfils these criteria with a sensitivity of
4 × 10-3 [32].
The viability of exfoliated cells and the ability of these
cells to become implanted and proliferated in the perito-
neum have been confirmed by several studies [33,34]. We
have not tested the viability of the tumour cells, because
we assume that they are all compromised after the lavage
treatment of sterilized water. A high diagnostic certainty is
essential for establishing microscopic peritoneal dissemi-
nation as a prognostic factor. A standard procedure of
peritoneal washing with sterile water subsequently fol-
lowed by saline water was done after operation. Given the
procedure and the sensitivity of the k-ras assay (limit is
reported to be 1% for the homoduplexes and 0.1% for the
heteroduplexes for a varity of target sequences), minor or
moderate bleeding in the surgical area could result in a
mutant fraction below the detection limit. One microliter
of blood contains an average of 5000 white blood cells,
hence if 10 millilitre of blood leaked into the lavage area,
50 000 k-ras positive tumour cells would be required for
detection. Albeit this stringent limitation, k-ras mutant
positive cells were regularly detected in lavage fluids from
the pelvic cavity. There are no known tumour-specific
markers for rectal cancer. K-ras is shown to be up-regu-
lated in epithelial tumour cells [35] and was used as a
marker for free tumour cells or cell remnants in the peri-
toneal cavity. The k-ras gene has a small hotspot region,
which makes it possible to detect 80–90% of k-ras gene
alterations with a simple PCR. However variation (20–
50%) of the prevalence of k-ras mutations in small spo-
radic colorectal adenomas have been reported in the liter-
ature [35]. Specific k-ras mutations induce different
biological consequences by affecting differently the struc-
tural confirmation and the function of the mutated pro-
tein [36,37]. For example, a number of studies have
demonstrated an impact of k-ras mutations for cancer pro-
gression and predispose to more aggressive biological
behaviour in patients with colorectal cancer [36,38-40].
K-ras mutations have also shown to be predictor of resist-
ance to the anti-epidermal growth factor receptor (cetuxi-Page 6 of 8
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prognosis [41].
In this study we found the frequency of k-ras mutations in
tumour to be 30% and one-third of these showed k-ras
mutations in the lavage fluid. Thus in 70% of these
patients a k-ras mutant is absent. Therefore other gene
mutations need to be investigated to obtain increased sen-
sitivity. To date as mention earlier there is no general
genetic marker that gives accurate information on the
prognostic impact for patients with rectal cancer. New
analyses of mutations or combinations of genes that are
specific for rectal carcinoma might lead to better candi-
dates. Detection of cancer specific markers in an abdomen
without visible tumour deposits and with a proven
increased risk of recurrence obviously imposes the ques-
tion of additional therapy either as intraoperative hyper-
thermic chemotherapy or systemic chemotherapy or any
combination of these. It should be remembered that this
is a pilot study that needs to be confirmed in an appropri-
ate multicenter study before therapeutic considerations
are carried out.
Conclusion
The overall clinical value of this molecular approach
needs further elucidation. The k-ras gene seems to be a
good genetic marker for detecting circulating tumour cells
from rectal cancer patients. However, studies with gene
markers covering a larger number of tumours are impor-
tant. Examination of lavage fluids before and after surgery
will further elucidate the mechanism of inducing exfoli-
ated tumour cells. If our results are confirmed, in the
future detection of disseminated cancer cells might enable
the selection of high-risk patients with poorer prognosis,
who would benefit from adjuvant treatment.
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